Augmentation (pharmacology)

This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources.
Find sources: "Augmentation" pharmacology – news · newspapers · books · scholar · JSTOR (August 2015) (Learn how and when to remove this message)

|

Augmentation, in the context of the pharmacological management of psychiatry, refers to the combination of two or more drugs to achieve better treatment results. Examples include:

* Prescribing an atypical antipsychotic when someone is already taking a selective serotonin reuptake inhibitor for the treatment of depression.[1]
* Prescribing estrogen for someone already being treated with antipsychotics for the management of schizophrenia.[2]
* Giving an adenosine A2A receptor antagonist on top of existing treatment for Parkinson's disease.[3]

In pharmacology, the term is occasionally used to describe treatments that increase (augment) the concentration of some substance in the body. This might be done when someone is deficient in a hormone, enzyme, or other endogenous substance. For example:

* Use of DDCIs in addition to L-DOPA, to reduce conversion of L-DOPA outside the brain.
* To give α1 antitrypsin to someone with alpha 1-antitrypsin deficiency.[4]

## References

[edit]

1. ^ Wright, BM; Eiland EH, 3rd; Lorenz, R (March 2013). "Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature". Pharmacotherapy. 33 (3): 344–59\. doi:10.1002/phar.1204. PMID 23456734. S2CID 2421659.`{{cite journal}}`: CS1 maint: numeric names: authors list (link)
2. ^ Begemann, MJ; Dekker, CF; van Lunenburg, M; Sommer, IE (November 2012). "Estrogen augmentation in schizophrenia: a quantitative review of current evidence". Schizophrenia Research. 141 (2–3): 179–84\. doi:10.1016/j.schres.2012.08.016. PMID 22998932. S2CID 40584474.2–3&rft.pages=179-84&rft.date=2012-11&rft_id=https://api.semanticscholar.org/CorpusID:40584474#id-name=S2CID&rft_id=info:pmid/22998932&rft_id=info:doi/10.1016/j.schres.2012.08.016&rft.aulast=Begemann&rft.aufirst=MJ&rft.au=Dekker,+CF&rft.au=van+Lunenburg,+M&rft.au=Sommer,+IE&rfr_id=info:sid/en.wikipedia.org:Augmentation+(pharmacology)" class="Z3988">
3. ^ Zhu, C; Wang, G; Li, J; Chen, L; Wang, C; Wang, Y; Lin, P; Ran, H (November 2014). "Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis". Neurological Research. 36 (11): 1028–34\. doi:10.1179/1743132814y.0000000375. PMID 24725292. S2CID 206852879.
4. ^ Campos, MA; Lascano, J (October 2014). "α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy". Therapeutic Advances in Respiratory Disease. 8 (5): 150–61\. doi:10.1177/1753465814542243. PMID 25013223. S2CID 32383294.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template